Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Case Study · April 02, 2022

Failure of Alemtuzumab Therapy in MOGAD

BMC Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

BMC Neurology
Failure of alemtuzumab therapy in three patients with MOG antibody associated disease
BMC Neurol 2022 Mar 09;22(1)84, SO Seneviratne, M Marriott, S Ramanathan, W Yeh, F Brilot-Turville, H Butzkueven, M Monif

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading